反応式
[CH3:1][C@@H:2]1[NH:7][CH2:6][CH2:5][N:4]([S:8]([C:11]2[CH:16]=[CH:15][C:14]([C:17]([F:20])([F:19])[F:18])=[CH:13][CH:12]=2)(=[O:10])=[O:9])[CH2:3]1.[CH3:21][C:22]1[CH:27]=[C:26]([C:28]([OH:30])=[O:29])[CH:25]=[CH:24][N:23]=1.C1C=CC2N(O)N=NC=2C=1.O.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C>CN(C=O)C>[CH:28]([OH:30])=[O:29].[CH3:1][C@H:2]1[CH2:3][N:4]([S:8]([C:11]2[CH:12]=[CH:13][C:14]([C:17]([F:20])([F:18])[F:19])=[CH:15][CH:16]=2)(=[O:9])=[O:10])[CH2:5][CH2:6][N:7]1[C:28]([C:26]1[CH:25]=[CH:24][N:23]=[C:22]([CH3:21])[CH:27]=1)=[O:29]参加物
8
反応物 6
生成物 1
試薬・触媒・溶媒 1
実験手順
To a solution of (3S)-3-methyl-1-{[4-(trifluoromethyl)phenyl]sulfonyl}piperazine (Description 2) (80 mg, 0.259 mmol) in DMF (5 ml) was added 2-methyl-4-pyridinecarboxylic acid (35.6 mg, 0.259 mmol), HOBT.H2O (39.7 mg, 0.259 mmol), HBTU (98 mg, 0.259 mmol) and DIPEA (0.136 ml, 0.778 mmol) and the reaction mixture was stirred at room temperature overnight. DMF was evaporated in vacuo then DCM (5 ml) was added and washed with saturated aq. NaHCO3 solution (5 ml), dried on a phase separation cartridge and evaporated in vacuo. The crude material was dissolved in MeCN/DMSO 1:1 and purified by MDAP. The desired fractions were collected and concentrated in vacuo giving the title compound (74 mg).
後処理
- customDMF was evaporated in vacuo
- additionDCM (5 ml) was added
- washwashed with saturated aq. NaHCO3 solution (5 ml)
- customdried on a phase separation cartridge
- customevaporated in vacuo
- dissolutionThe crude material was dissolved in MeCN/DMSO 1:1
- custompurified by MDAP
- customThe desired fractions were collected
- concentrationconcentrated in vacuo
出典と根拠
- ORDレコード
- ord-43d2502aae1d4b49bf668f12fc6946c8
- 出典データセット
- uspto-grants-2013_09
- 特許番号
- US08530478B2
関連ノート
読み込み中…